OBJECTIVE: Persistent villous atrophy in patients with celiac disease (CD) on a gluten-free diet (GFD) is reported with increasing frequency. The aim of this study was to evaluate a possible association between persistent damage of the villi and "atypical" gastrointestinal symptoms in CD patients on a GFD. MATERIAL AND METHODS: Sixty-nine CD patients on a GFD were divided into two groups: Group A included 42 patients (6 M, 36 F, age range 17-62 years) undergoing esophagogastroduodenoscopies (EGDs) due to the presence of symptoms; Group B included 27 control patients (6 M, 21 F, age range 24-71 years) who were asymptomatic at the time of the study. Both groups underwent EGDs and a duodenal histologic study. RESULTS: Persistent endoscopic lesions were more frequent in Group A (30/42) than in Group B (12/27; p=0.01). Villous atrophy was significantly more frequent in Group A than in Group B: 85% versus 33% (p<0.0001; odds ratio (OR)=12; 95% CI 3.7-38.9). Gastrointestinal symptoms in the Group A patients were different from those present at CD diagnosis: anemia/diarrhea/weight loss in 6 cases; gastroesophageal reflux disease (GERD)-like symptoms in 12 cases; abdominal pain/constipation in 24 cases. In Group A there was no difference in gender distribution, age and duration of GFD between subjects with normal villi and those with persistent partial villous atrophy. Patients with persistent symptoms showed a higher intraepithelial eosinophil count (p=0.005) than the asymptomatic patients (p=0.01). CONCLUSIONS: Persistent intestinal villous atrophy in CD patients on a GFD is associated with gastrointestinal symptoms considered "atypical" for CD and not present at CD diagnosis.
OBJECTIVE: Persistent villous atrophy in patients with celiac disease (CD) on a gluten-free diet (GFD) is reported with increasing frequency. The aim of this study was to evaluate a possible association between persistent damage of the villi and "atypical" gastrointestinal symptoms in CDpatients on a GFD. MATERIAL AND METHODS: Sixty-nine CDpatients on a GFD were divided into two groups: Group A included 42 patients (6 M, 36 F, age range 17-62 years) undergoing esophagogastroduodenoscopies (EGDs) due to the presence of symptoms; Group B included 27 control patients (6 M, 21 F, age range 24-71 years) who were asymptomatic at the time of the study. Both groups underwent EGDs and a duodenal histologic study. RESULTS: Persistent endoscopic lesions were more frequent in Group A (30/42) than in Group B (12/27; p=0.01). Villous atrophy was significantly more frequent in Group A than in Group B: 85% versus 33% (p<0.0001; odds ratio (OR)=12; 95% CI 3.7-38.9). Gastrointestinal symptoms in the Group A patients were different from those present at CD diagnosis: anemia/diarrhea/weight loss in 6 cases; gastroesophageal reflux disease (GERD)-like symptoms in 12 cases; abdominal pain/constipation in 24 cases. In Group A there was no difference in gender distribution, age and duration of GFD between subjects with normal villi and those with persistent partial villous atrophy. Patients with persistent symptoms showed a higher intraepithelial eosinophil count (p=0.005) than the asymptomatic patients (p=0.01). CONCLUSIONS: Persistent intestinal villous atrophy in CDpatients on a GFD is associated with gastrointestinal symptoms considered "atypical" for CD and not present at CD diagnosis.
Authors: Jonas F Ludvigsson; Tim Card; Paul J Ciclitira; Gillian L Swift; Ikram Nasr; David S Sanders; Carolina Ciacci Journal: United European Gastroenterol J Date: 2015-04 Impact factor: 4.623
Authors: Francisco Cabrera-Chávez; Stefania Iametti; Matteo Miriani; Ana M Calderón de la Barca; Gianfranco Mamone; Francesco Bonomi Journal: Plant Foods Hum Nutr Date: 2012-03 Impact factor: 3.921
Authors: Jocelyn A Silvester; Satya Kurada; Andrea Szwajcer; Ciarán P Kelly; Daniel A Leffler; Donald R Duerksen Journal: Gastroenterology Date: 2017-05-22 Impact factor: 22.682
Authors: Zsolt Szakács; Péter Mátrai; Péter Hegyi; Imre Szabó; Áron Vincze; Márta Balaskó; Bernadett Mosdósi; Patrícia Sarlós; Mária Simon; Katalin Márta; Alexandra Mikó; Dániel Pécsi; Alexandra Demcsák; Judit Bajor Journal: PLoS One Date: 2017-11-02 Impact factor: 3.240
Authors: Giacomo Caio; Umberto Volta; Anna Sapone; Daniel A Leffler; Roberto De Giorgio; Carlo Catassi; Alessio Fasano Journal: BMC Med Date: 2019-07-23 Impact factor: 8.775
Authors: Zsolt Szakács; Noémi Gede; Zoltán Gyöngyi; Margit Solymár; Dezső Csupor; Bálint Erőss; Áron Vincze; Alexandra Mikó; Andrea Vasas; László Szapáry; Dalma Dobszai; Viktória Balikó; Roland Hágendorn; Péter Hegyi; Judit Bajor Journal: Front Physiol Date: 2019-11-19 Impact factor: 4.566